An observational study in Febrile Neutropenia, Acute Leukemia and Stem Cell Transplantation, sponsored by Pathoquest. Status unknown at 5 sites in France. Open to participants aged 5 Years and older. Per ClinicalTrials.gov, last updated 2019-03-21.
Sponsored by Pathoquest · Observational
Among 16 studies in Febrile Neutropenia with a site in France — 1 open to participants now, 1 under way, 1 of them phase 3. Febrile Neutropenia · France.
Among the 16 studies in Febrile Neutropenia with a site in France, this one is the 8th largest by planned enrollment of the 10 observational ones, is one of 2 that started in 2018, is one of 10 observational ones, and was the 9th registered.
147 studies on the registry are indexed under Febrile Neutropenia; 36 are open to participants now.
This study's planned enrollment of 97 is below the median of 131 across 46 observational studies indexed under Febrile Neutropenia.
Browse Febrile Neutropenia studies →1 of the 16 studies in Febrile Neutropenia with a site in France is open now, in 1 country. Each count lists the studies.
Of the 19 Febrile Neutropenia studies recruiting now, 11 (58%) set no upper age limit and 8 (42%) stop at 75 or younger; 4 take children under 18; 0 take healthy volunteers.
This study: 5 Years and older · all sexes · no healthy volunteers.
The full table on the hub →16 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 2 started in 2018.
Median enrollment 484 across the 6 interventional studies, 122 across the 10 observational. Of the 14 that completed or were terminated, 2 (14%) have results posted.
3 of 16 have an industry lead sponsor. The 10 most frequent:
Pathoquest is the lead sponsor of 2 studies on the registry; none are open to participants now.
Pathoquest has 1 study filed under Febrile Neutropenia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 16 studies in Febrile Neutropenia with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
Prospective, multicentre French observational study assessing the performance and medico-economic utility of iDTECT Blood versus conventional microbiologic diagnosis in patients with febrile neutropenia
Febrile neutropenic patients suspected of sepsis will follow the conventional infectious diagnosis work-up over the entire observation period, and will be tested in addition with iDTECT Blood on Study Day 1.
Patients treated with chemotherapy for Acute Leukaemia (AL) or Myelodysplastic Syndrome (MDS) or in the context of hematopoietic stem cell transplantation (HSCT), presenting a febrile neutropenic episode and suspected of infection
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Next generation sequencing-based shot-gun metagenomic test for the diagnosis of viral or bacterial infections using blood samples
Rate of detection of clinically relevant bacterial or viral pathogen (CRBV) by iDTECT™ Blood as compared to conventional microbiological methods at inclusion
Sensitivity, specificity, negative predictive value, positive predictive value at inclusion
Time frame: 7 months
Antiobiotic use
Type of antibiotic, duration of antibiotic course
Time frame: 9 months
Plan to share: Undecided
No publications or documents are linked to this record.
Started May 2018 (actual). Primary completion is estimated for Apr 2019, 11 months after the start.
Of 21 observational studies under Febrile Neutropenia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 60. This study's planned 11 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pathoquest